Health Catalyst, Inc.
Health Catalyst, Inc.（HCAT）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
hcat · 股价预测 · 22 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 22 位华尔街分析师
Buy
22 位分析师
共识
评级分布
12 个月目标价
High
$3.00
Consensus
$2.25
+30.1% upside
Low
$1.75
Median: $2 · Last Close: $1.73
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$2.25
30.1% upside
High Target
$3
73.4%
Low Target
$1.75
1.2%
Current Price
$1.73
as of today
Based on analyst price targets, the HCAT stock price prediction for the next 12 months ranges from $1.75 to $3. The consensus HCAT price forecast of $2.25 implies 30.1% upside from the current price of $1.73.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.73 | ↑ 0.00% |
1-day model range: $1.71–$1.75. Peak: $1.75 (+0.00%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HCAT · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-12 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2026-03-18 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2026-03-13 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2026-03-13 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2026-03-13 | Citigroup | Maintains | Neutral→Neutral |
| 2026-03-13 | Stifel | Maintains | Hold→Hold |
| 2026-03-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-01-09 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-11 | Stifel | Maintains | Hold→Hold |
| 2025-11-11 | Citigroup | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Health Catalyst, Inc. (HCAT) stock. Of the recent 146 rating actions, 8 were upgrades and 14 were downgrades. 22 analysts currently cover HCAT.
分析师推荐趋势
HCAT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$307M
↑ 16.5% YoY
Revenue Next Year
$310M
↑ 1.3% YoY
EPS This Year
$0.31
EPS Next Year
$0.20
↓ 36.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast HCAT EPS of $0.31 for the current fiscal year, based on estimates from 9 analysts. The HCAT revenue forecast is $307M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
HCAT 股价预测由两类独立数据源支撑：来自 22 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。HCAT 的共识目标价为 $2.25（+30.1% 上行空间），分析师共识为 Buy。
HCAT 的短期预测（明日）为 $1.73（+0.00%）。
Health Catalyst, Inc. 在 NASDAQ 上市，代码 HCAT。HCAT 在 2027 年的整体展望偏积极，在覆盖分析师中约 55% 对应 Buy 共识。
常见问题
HCAT 预测 · 8 个问题根据 22 位华尔街分析师，HCAT 的 12 个月平均目标价为 $2.25，最高 $3.00、最低 $1.75。若有图表，中位目标价可在上方查看。相对当前价 $1.73，隐含约 +30.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.